NeuroBo Pharmaceuticals, Inc.
(NASDAQ : NRBO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -0.39%332.310.0%$4435.70m
BNTXBioNTech SE 2.27%268.820.0%$739.63m
NVAXNovavax, Inc. -15.94%134.9679.4%$597.74m
AMGNAmgen, Inc. 1.21%209.281.4%$552.92m
SNSSSunesis Pharmaceuticals, Inc. 3.58%6.360.7%$444.59m
REGNRegeneron Pharmaceuticals, Inc. 1.51%560.432.7%$438.08m
GILDGilead Sciences, Inc. -0.02%66.891.0%$413.00m
CCXIChemoCentryx, Inc. 4.34%35.112.9%$402.07m
ILMNIllumina, Inc. -0.29%412.903.3%$373.56m
XLRNAcceleron Pharma, Inc. -0.62%172.675.3%$348.17m
VRTXVertex Pharmaceuticals, Inc. 0.11%185.611.9%$270.05m
BIIBBiogen, Inc. -0.84%265.871.7%$241.48m
OCGNOcugen, Inc. 5.27%8.770.0%$185.73m
XENEXenon Pharmaceuticals, Inc. 1.98%30.400.4%$163.55m
CRSPCRISPR Therapeutics AG -1.77%98.490.6%$159.26m

Company Profile

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline include ANA001, a proprietary oral niclosamide formulation; Gemcabene, which is assessed as an acute indication for COVID-19; NB-01, a treatment for painful diabetic neuropathy; and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Boston, MA.